253 related articles for article (PubMed ID: 28107393)
21. Molecular mechanisms for Kv1.3 potassium channel current inhibition by CD3/CD28 stimulation in Jurkat T cells.
Matsushita Y; Ohya S; Itoda H; Kimura T; Suzuki Y; Yamamura H; Imaizumi Y
Biochem Biophys Res Commun; 2008 Sep; 374(1):152-7. PubMed ID: 18611390
[TBL] [Abstract][Full Text] [Related]
22. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Beeton C; Wulff H; Standifer NE; Azam P; Mullen KM; Pennington MW; Kolski-Andreaco A; Wei E; Grino A; Counts DR; Wang PH; LeeHealey CJ; S Andrews B; Sankaranarayanan A; Homerick D; Roeck WW; Tehranzadeh J; Stanhope KL; Zimin P; Havel PJ; Griffey S; Knaus HG; Nepom GT; Gutman GA; Calabresi PA; Chandy KG
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17414-9. PubMed ID: 17088564
[TBL] [Abstract][Full Text] [Related]
23. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
24. Characterization and molecular basis for the block of Kv1.3 channels induced by carvedilol in HEK293 cells.
Yang JF; Cheng N; Ren S; Liu XM; Li XT
Eur J Pharmacol; 2018 Sep; 834():206-212. PubMed ID: 30016664
[TBL] [Abstract][Full Text] [Related]
25. The inhibitory effect of copper ions on lymphocyte Kv1.3 potassium channels.
Teisseyre A; Mozrzymas JW
J Physiol Pharmacol; 2006 Jun; 57(2):301-14. PubMed ID: 16845233
[TBL] [Abstract][Full Text] [Related]
26. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
Koo GC; Blake JT; Shah K; Staruch MJ; Dumont F; Wunderler D; Sanchez M; McManus OB; Sirotina-Meisher A; Fischer P; Boltz RC; Goetz MA; Baker R; Bao J; Kayser F; Rupprecht KM; Parsons WH; Tong XC; Ita IE; Pivnichny J; Vincent S; Cunningham P; Hora D; Feeney W; Kaczorowski G
Cell Immunol; 1999 Nov; 197(2):99-107. PubMed ID: 10607427
[TBL] [Abstract][Full Text] [Related]
27. Genistein inhibits the activity of kv1.3 potassium channels in human T lymphocytes.
Teisseyre A; Michalak K
J Membr Biol; 2005 May; 205(2):71-9. PubMed ID: 16283587
[TBL] [Abstract][Full Text] [Related]
28. Targeting effector memory T-cells with Kv1.3 blockers.
Wulff H; Pennington M
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
[TBL] [Abstract][Full Text] [Related]
29. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
30. Kv1.3 channels as a potential target for immunomodulation of CD4+ CD28null T cells in patients with acute coronary syndrome.
Xu R; Cao M; Wu X; Wang X; Ruan L; Quan X; Lü C; He W; Zhang C
Clin Immunol; 2012 Feb; 142(2):209-17. PubMed ID: 22169811
[TBL] [Abstract][Full Text] [Related]
31. Cortisone and hydrocortisone inhibit human Kv1.3 activity in a non-genomic manner.
Yu J; Park MH; Choi SY; Jo SH
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):653-61. PubMed ID: 25743574
[TBL] [Abstract][Full Text] [Related]
32. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
33. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels.
Toldi G; Vásárhelyi B; Kaposi A; Mészáros G; Pánczél P; Hosszufalusi N; Tulassay T; Treszl A
Immunol Lett; 2010 Sep; 133(1):35-41. PubMed ID: 20603149
[TBL] [Abstract][Full Text] [Related]
34. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.
Harvey AJ; Baell JB; Toovey N; Homerick D; Wulff H
J Med Chem; 2006 Feb; 49(4):1433-41. PubMed ID: 16480279
[TBL] [Abstract][Full Text] [Related]
35. Blockade action of ketanserin and increasing effect of potassium ion on Kv1.3 channels expressed in Xenopus oocytes.
Wang X; Liao Y; Zou A; Li L; Tu D
Pharmacol Res; 2007 Aug; 56(2):148-54. PubMed ID: 17582781
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes: a possible role in T cell proliferation.
Conforti L; Petrovic M; Mohammad D; Lee S; Ma Q; Barone S; Filipovich AH
J Immunol; 2003 Jan; 170(2):695-702. PubMed ID: 12517930
[TBL] [Abstract][Full Text] [Related]
37. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
38. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of the selective serotonin reuptake inhibitor paroxetine on human Kv1.3 channels.
Hwang S; Kim JH; Jo SH
Eur J Pharmacol; 2021 Dec; 912():174567. PubMed ID: 34662565
[TBL] [Abstract][Full Text] [Related]
40. Peptide blockers of K
Chandy KG; Norton RS
Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
